Pathological gambling in a patient on piribedil: A case report. Issue 6 (12th February 2021)

• Record Type: Journal Article
• Authors: Wang, Yingtan; Lu, Zhe; Xun, Guanglei
• Other Names: Saranathan. Maya section editor.
• Is Part Of: Medicine. Volume 100:Issue 6(2021)
• Publication Date: 2021-02-12
• Subjects: case report -- depressive disorder -- dopamine partial agonist -- gambling disorder -- Parkinson disease -- pathological gambling -- piribedil; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000024568
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Rationale: Piribedil is an orally active dopamine agonist that has been widely used for Parkinson disease (PD), with its partial D2/D3 agonistic functions and alpha2-adrenoreceptor antagonistic effects, piribedil has been proved to be efficacious in the relief of motor symptoms in PD, while it can also lead to impulse control disorders such as pathological gambling due to its dopamine agonistic effects. Patient concerns: A 28-year-old Chinese female patient with Parkinson disease and a history of taking piribedil finally developed pathological gambling and depressive episode. Diagnoses: After a careful clinical observation and evaluation, the patient met the criteria of severe depressive episode and pathological gambling due to antiparkinson therapy. Interventions: We discontinued piribedil and picked bupropion, a dopamine reuptake inhibitor, to alleviate the depressive symptom. Benzhexol and selegiline were also added for the control of motor fluctuations. Outcomes: After 3 weeks' treatment, the patient's depressive mood was significantly alleviated and her recurring PD symptoms were also relieved. She was no more addicted to network gambling, and there was no recurrence during the 1-year follow-up. Lessons: Piribedil-induced problem gambling and impulse control disorders are side effects needed to be evaluated when commencing a patient on piribedil. This case further emphasizes the importance of monitoring and controlling Parkinson symptoms after drug reduction or withdrawal. Anticipation of this risk strengthens the significance of detailed medical history-taking and targeted clinical management.